Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Br J Nutr ; 129(11): 1888-1896, 2023 06 14.
Artigo em Inglês | MEDLINE | ID: mdl-36274637

RESUMO

Sarcopenia is more common in the elderly and causes adverse outcomes with increased morbidity and mortality. This prospective cohort study assessed the association of sarcopenia risk with the severity of COVID-19 at the time of admission and during hospitalisation and the length of hospital stay. Two hundred patients (aged ≥ 60 years) who were hospitalised for COVID-19 were enrolled using consecutive sampling between 29 December 2020 and 20 May 2021. The sarcopenia score of the patients was assessed using the Strength, Assistance in walking, Rising from a chair, Climbing stairs, and Falls questionnaire. The severity of COVID-19 was determined using the modified National Early Warning Score (m-NEWS) system for 2019 n-CoV-infected patients at admission (T1), day three (T2) and at discharge (T3). Data were analysed using SPSS, version 22 and STATA, version 14. Of the 165 patients included, thirty four (20·6 %) were at risk of sarcopenia. The length of hospital stay was slightly longer in patients with sarcopenia risk, but the difference was not significant (P = 0·600). The adjusted OR of respiratory rate (RR) > 20 /min at T1 for the sarcopenia risk group was 6·7-times higher than that for the non-sarcopenic group (P = 0·002). According to generalised estimating equations, after adjusting for confounding factors, the m-NEWS score was 5·6 units higher in patients at risk of sarcopenia (P < 0·001). Sarcopenia risk could exacerbate COVID-19 severity and increase RR at admission, as well as the need for oxygen therapy at discharge.


Assuntos
COVID-19 , Sarcopenia , Idoso , Humanos , Sarcopenia/complicações , Sarcopenia/epidemiologia , Tempo de Internação , Estudos Prospectivos , COVID-19/complicações , COVID-19/epidemiologia , Inquéritos e Questionários , Avaliação Geriátrica
2.
Diabetes Metab Syndr ; 15(5): 102224, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34403949

RESUMO

BACKGROUND AND AIMS: Silent information regulator 1 (Sirt1) involved in histone stability, transcriptional activity, and translocation. This systematic review aimed to summarize the effects of Resveratrol on Sirt1 expression. MATERIALS AND METHODS: Electronic databases including Scopus, Medline and web of knowledge were searched up to March 2020. RESULTS: Out of 801 studies identified in our search finally 12 articles included. Totally six studies evaluated the effects of resveratrol on SIRT1 gene expression, and six articles investigate protein expression. CONCLUSION: The results of the included studies showed that resveratrol supplementation had beneficial effects on protein and gene expression of SIRT1.


Assuntos
Antioxidantes/farmacologia , Suplementos Nutricionais , Regulação da Expressão Gênica/efeitos dos fármacos , Resveratrol/farmacologia , Sirtuína 1/metabolismo , Antioxidantes/administração & dosagem , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patologia , Humanos , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Inflamação/patologia , Obesidade/tratamento farmacológico , Obesidade/metabolismo , Obesidade/patologia , Prognóstico , Resveratrol/administração & dosagem , Sirtuína 1/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA